The selling is concentrated in a director and a venture capital holder, which may reflect portfolio rebalancing or a 10b5-1 plan rather than a negative view on the company. Monitor for any subsequent filings (e.g., Form 144 or 8-K) that could indicate a broader sell-off or material news. Given the strong analyst consensus and lack of insider buying, the stock is likely to trade on fundamentals rather than this insider activity.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 4 $7.24entry
- T+1 · 3mo ago −2.49%α −2.29% · $7.06
- T+5 · 3mo ago −2.76%α −2.66% · $7.04
- T+20 · 3mo ago −2.35%α −1.11% · $7.07
- T+60 · 20d ago −39.09%α −38.87% · $4.41
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at Entrada Therapeutics (Director Kush Parmar and 10% owner 5AM Ventures) sold a combined $1.59M in open-market sales over two days, representing ~0.6% of the company's $264M market cap. This is a significant cluster of selling by a director and a major venture holder, but the dollar amount is modest relative to market cap and the sales are likely part of a pre-arranged plan or liquidity event rather than a bearish signal. The stock has a strong analyst consensus (86% bullish) and recent insider activity includes $1.6M in sales over 30 days, suggesting a pattern of routine selling rather than a new negative development.
Key Financial Metrics
Key Facts
- Director Kush Parmar sold 114,756 shares at $6.93 on 2026-07-30 for $795K
- 5AM Ventures V, L.P. sold 114,756 shares at $6.93 on 2026-07-30 for $795K
- Total cluster value: $1.59M, representing ~0.6% of $264M market cap
- Both insiders also sold 1,718 shares each at $6.85 on 2026-07-31 for ~$11.8K total
- Net direction is selling; no insider buying in the cluster
Financial Impact
Insider sales of $1.59M represent ~0.6% of market cap, a modest but notable amount
Risk Factors
- Continued insider selling could signal lack of confidence if it accelerates
- Venture capital selling may pressure the stock if not absorbed by institutional demand
- No insider buying to offset the selling pattern
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-TRDA-1785814363438 |
Track record
21 reports on TRDA
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +58.22% at T+20 after the May 4, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $4.55 Now $5.00 +9.89% settles Feb 3
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $4.55 Now $5.00 +9.89% settles Jan 11
- Sep 9, 20269w ago Insider Cluster Bearish 6/10 Entry $6.42 Now $5.00 +22.12% settles Dec 4
- Sep 3, 202610w ago Insider Cluster Neutral 3/10 Entry $7.13 Now $5.00 −29.87% settles Dec 1
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 3/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $7.27 Now $5.00 −31.22% settles Nov 20
- Aug 10, 202614w ago Insider Cluster Neutral 2/10 Entry $7.04 to $5.06 Now $5.00 −28.98% ▼ −28.13% −27.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers